Science news
Experienced Global Pharma Industry Leader, Prof Fiona Randall, joins the Alzheimer’s Research UK UCL Drug Discovery Institute as Chief Scientific Officer
Prof Fiona Randall has been appointed as Chief Scientific Officer (CSO) for Alzheimer’s Research UK’s University College London Drug Discovery Institute (UCL DDI)
Air pollution and dementia risk review suggests particulate matter has greatest effect
Researchers in Canada have carried out a review of existing evidence of a link between dementia and air pollution.
Does diet really affect our dementia risk?
Research published today (Wednesday 12 October) suggests that following a Mediterranean diet does not reduce risk of dementia, including Alzheimer’s disease and vascular dementia.
Omega-3 intake in midlife reduced dementia risk
A new research study conducted in the US suggests that people who have higher levels omega-3 fatty acids in their blood during midlife have better thinking skills than people who have lower levels of the fatty acid.
‘Concerning’ links between former international rugby players and neurodegeneration revealed
Today (Tuesday 4 October) research conducted at University of Glasgow finds a group of former international rugby players are at around two and a half times higher risk of dementia, and over 15 times greater risk of Motor Neuron Disease, compared to the general population.
Does a specific form of amyloid protect us from memory and thinking problems?
Research in the US published today (Tuesday 4 October) suggests that the presence of high levels of a form of the amyloid protein – soluble Aβ42 – in the brain could reduce the risk of memory and thinking problems in people who have high genetic risk of developing Alzheimer’s disease.
Could being a ‘superager’ prevent memory and thinking problems in later life?
Research in the US published today (Friday 30 September) suggest that the brain cells of ‘superagers’ may hold the key to resisting memory and thinking problems later in life.
New hope as Alzheimer’s drug slows memory decline in phase 3 trial
“Historic moment” for dementia research as Alzheimer’s drug – lecanemab – is first in a generation to successfully meet its primary endpoints in phase 3 clinical trial
Early career researcher in Keele backed to investigate how metals in the brain are linked to Alzheimer’s disease
Alzheimer’s Research UK is announcing new funding for a research project at Keele University to investigate how metal nanoparticles contribute to Alzheimer’s disease.
Oxford scientist awarded £420K funding boost from leading dementia research charity
Today, Alzheimer’s Research UK has announced support for pioneering dementia research at the University of Oxford.
